908 Devices (MASS)
(Delayed Data from NSDQ)
$5.32 USD
-0.02 (-0.37%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $5.33 +0.01 (0.19%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum F VGM
Price, Consensus and EPS Surprise
MASS 5.32 -0.02(-0.37%)
Will MASS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MASS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MASS
Wall Street Analysts Predict a 133.69% Upside in 908 Devices (MASS): Here's What You Should Know
908 Devices (MASS) Loses -9.95% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
MASS: What are Zacks experts saying now?
Zacks Private Portfolio Services
908 Devices Inc. (MASS) Reports Q1 Loss, Tops Revenue Estimates
IQVIA Holdings (IQV) Reports Next Week: Wall Street Expects Earnings Growth
Intuitive Surgical, Inc. (ISRG) Q1 Earnings and Revenues Top Estimates
Other News for MASS
908 Devices Appoints Michele M. Leonhart, Former Administrator of the United States Drug Enforcement Administration (DEA), to Its Board of Directors
908 Devices appoints Leonhart to Board of Directors
908 Devices Enhances XplorIR Portable Analyzer to Simultaneously Identify and Quantify Hazardous Gases and Vapors
908 Devices announce enhanced qualification package for XplorIR
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), 908 Devices (MASS) and Nurix Therapeutics (NRIX)